Estimate Your Nausea Risk
All calculations happen in your browser. Nothing stored or transmitted.
Estimated nausea probability
Nausea Rates by Drug — Clinical Trial Data
| Drug | Nausea Rate | Vomiting Rate | Trial |
|---|---|---|---|
| Wegovy (semaglutide 2.4mg) | 44% | 24% | STEP 1 |
| Ozempic (semaglutide 1mg) | ~20% | ~8% | SUSTAIN-1 |
| Saxenda (liraglutide 3mg) | ~38% | ~14% | SCALE |
| Zepbound (tirzepatide 15mg) | 18% | 9% | SURMOUNT-1 |
| Mounjaro (tirzepatide 15mg) | ~15% | ~6% | SURPASS-1 |
💡 Tirzepatide (Mounjaro/Zepbound) causes roughly 2–3x less nausea than semaglutide (Ozempic/Wegovy). If you're concerned about nausea and can access either drug, tirzepatide is the significantly better-tolerated option.
Known Nausea Risk Factors
Factors That Increase Nausea Risk
- Female biological sex: Women consistently report higher rates of GI side effects on GLP-1 medications across all clinical trials
- History of motion sickness: Indicates a more sensitive vestibular-GI nausea pathway — strongly predictive of GLP-1 nausea
- History of GERD or acid reflux: GLP-1-induced delayed gastric emptying worsens pre-existing reflux and increases nausea
- High-fat meals: Fat combined with delayed gastric emptying dramatically increases nausea risk
- Large meal sizes: Overfilling a stomach with already-slowed emptying is a primary nausea trigger
- Morning injection: Peak drug concentration occurs during waking hours — maximizing nausea awareness
- Alcohol consumption: Alcohol irritates the GI tract and compounds GLP-1 nausea significantly
- Semaglutide vs tirzepatide: Semaglutide causes 2–3x more nausea than tirzepatide at comparable weight-loss doses
Factors That Reduce Nausea Risk
- Bedtime injection — sleeping through the peak nausea window
- Small, lean meals especially on injection day
- No alcohol
- Choosing tirzepatide over semaglutide
- Strict adherence to the dose escalation schedule — never rushing
- Staying well hydrated throughout the day
- Ginger supplementation (tea, chews, capsules) — evidence-backed for GI nausea
Frequently Asked Questions
Nausea affects approximately 44% of Wegovy users and 20–30% of Ozempic users in clinical trials. It is most common during dose escalation and typically improves significantly by weeks 6–10. Tirzepatide (Mounjaro/Zepbound) causes significantly less nausea at around 15–18%.
Yes — for most people nausea improves significantly within 4–8 weeks as the body adapts. The dose escalation protocol allows gradual GI tract adaptation. Most patients report nausea is mild or absent by the time they reach their maintenance dose. About 5–10% experience persistent nausea leading to discontinuation.
Yes — significantly. Tirzepatide causes nausea in approximately 15–18% of patients compared to 30–44% for semaglutide. The GIP receptor component of tirzepatide appears to counteract some of the GLP-1-induced nausea.
The single most effective strategy is injecting before bedtime — you sleep through the 4–8 hour peak nausea window. Also: eat smaller, slower meals; avoid fatty and sugary foods on injection day; stay upright for 1+ hour after eating; stay hydrated; avoid alcohol; and consider ginger tea or chews.